Ocular inflammation and pain Pipeline Analysis and Clinical Trials Assessment, 2025 by DelveInsight | Formosa Pharmaceuticals, Inc., Sun Pharma Advanced Research Company Limited, Sun Pharma Global FZE, A.T. Resolve SARL, Tarsius Pharma, SALVAT

Ocular inflammation and pain Pipeline constitutes 5+ key companies continuously working towards developing 5+ Ocular inflammation and pain treatment therapies, analyzes DelveInsight.

Ocular inflammation and pain Overview:

Inflammation is the body's natural response to injury, infection, or irritation. In some cases, it can occur due to harmless substances, like dust, pollen, or grass, leading to an allergic reaction. The immune system may also cause inflammation when it mistakenly attacks the body's own tissues, known as an autoimmune response. Eye inflammation can result from infection, allergies, autoimmune conditions, irritation, or trauma to the eye or eyelid. Symptoms may affect the eyes, eyelids, or surrounding areas and include blurred vision, pain, redness, swelling, tearing, and unusual warmth. Ocular inflammation is commonly seen in patients with systemic inflammatory conditions, such as rheumatoid arthritis, lupus, sarcoidosis, Wegener's granulomatosis, Sjögren's syndrome, and others.

Download our report @ https://www.delveinsight.com/report-store/ocular-inflammation-and-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Ocular inflammation and pain Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Ocular inflammation and pain Therapeutics Market.

Key Takeaways from the Ocular inflammation and pain Pipeline Report

DelveInsight's Ocular inflammation and pain pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Ocular inflammation and pain treatment.
Approved on March 4, 2024, this corticosteroid ophthalmic suspension is indicated for the treatment of post-operative inflammation and pain following ocular surgery. In clinical studies, ocular adverse reactions occurring in ≥1% of subjects included eye inflammation (2%), corneal edema (2%), anterior chamber inflammation (2%), cystoid macular edema (2%), intraocular pressure elevation (1%), photophobia (1%), and vitreous detachment (1%) .​
Approved on May 18, 2023, MIEBO is a first-in-class treatment for the signs and symptoms of dry eye disease (DED). DED is a multifactorial, age-related, chronic progressive disease of the ocular surface. MIEBO is indicated for the treatment of the signs and symptoms of dry eye disease .​
Key Ocular inflammation and pain companies such as Formosa Pharmaceuticals, Inc., Sun Pharma Advanced Research Company Limited, Sun Pharma Global FZE, A.T. Resolve SARL, Tarsius Pharma, SALVAT, and others are evaluating new drugs for Ocular inflammation and pain to improve the treatment landscape.
Promising Ocular inflammation and pain therapies include APP13007, and others.

Ocular inflammation and pain Pipeline Analysis
The Ocular inflammation and pain pipeline insights report 2025, provides insights into:
Provides comprehensive insights into key companies developing therapies in the Ocular inflammation and pain Market.

Categorizes Ocular inflammation and pain therapeutic companies by development stage: early, mid, and late-stage.

Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

Reviews emerging Ocular inflammation and pain drugs under development based on:

Stage of development

Ocular inflammation and pain Route of administration

Target receptor

Monotherapy vs. combination therapy

Ocular inflammation and pain Mechanism of action

Molecular type

Offers detailed analysis of:

Company-to-company and company-academia collaborations

Ocular inflammation and pain Licensing agreements

Funding and investment activities supporting future Ocular inflammation and pain market advancement.

Request for a sample report @ https://www.delveinsight.com/sample-request/ocular-inflammation-and-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Ocular inflammation and pain Emerging Drugs

APP13007: Formosa pharmaceuticals

APP13007, developed from our proprietary APNT formulation platform, is an aqueous-based ophthalmic nanosuspension designed to treat post-operative pain and inflammatory eye conditions. Its active ingredient is a potent corticosteroid with over 30 years of established efficacy and safety for dermatological use in the US, Europe, and Japan. APP13007 marks the first ophthalmic use of this well-known active ingredient. After completing Phase II studies in 2020, it began Phase III trials in the United States in March 2022.

Ocular inflammation and pain Companies

Around five or more key companies are working on therapies for ocular inflammation and pain. Among them, Formosa Pharmaceuticals has drug candidates in the most advanced stage, currently in Phase III.

DelveInsight's report covers around 5+ products under different phases of Ocular inflammation and pain clinical trials like

Ocular inflammation and pain Late stage Therapies (Phase III)
Ocular inflammation and pain Mid-stage Therapies (Phase II)
Ocular inflammation and pain Early-stage Therapies (Phase I)
Ocular inflammation and pain Pre-clinical and Ocular inflammation and pain Discovery stage Therapies
Ocular inflammation and pain Discontinued & Inactive Therapies

Ocular inflammation and pain pipeline report provides the Ocular inflammation and pain therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Ocular inflammation and pain Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Ocular inflammation and pain Therapies and Key Ocular inflammation and pain Companies: Ocular inflammation and pain Clinical Trials and recent advancements https://www.delveinsight.com/report-store/ocular-inflammation-and-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Ocular inflammation and pain Pipeline Therapeutic Assessment
• Ocular inflammation and pain Assessment by Product Type
• Ocular inflammation and pain By Stage
• Ocular inflammation and pain Assessment by Route of Administration
• Ocular inflammation and pain Assessment by Molecule Type

Download Ocular inflammation and pain Sample report to know in detail about the Ocular inflammation and pain treatment market @ Ocular inflammation and pain Therapeutic Assessment https://www.delveinsight.com/sample-request/ocular-inflammation-and-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Ocular inflammation and pain Current Treatment Patterns
4. Ocular inflammation and pain - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Ocular inflammation and pain Late-Stage Products (Phase-III)
7. Ocular inflammation and pain Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Ocular inflammation and pain Discontinued Products
13. Ocular inflammation and pain Product Profiles
14. Ocular inflammation and pain Key Companies
15. Ocular inflammation and pain Key Products
16. Dormant and Discontinued Products
17. Ocular inflammation and pain Unmet Needs
18. Ocular inflammation and pain Future Perspectives
19. Ocular inflammation and pain Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Ocular inflammation and pain Pipeline Reports Offerings: https://www.delveinsight.com/report-store/ocular-inflammation-and-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.